Moderna, Inc. (MRNA)

Moderna's stock price has fluctuated over the past six months. The stock increased by 20.47% over the last six months and 14.92% over the past year as of January 13, 2026. Positive movements include a premarket stock increase following the Q3 2025 earnings report and a surge after the CEO revealed plans for a combined flu and COVID-19 vaccine. The submission of regulatory filings for its seasonal influenza vaccine also led to a rise in shares. The stock faced downward pressure after announcing plans to cut R&D spending and pushing back its breakeven guidance. Declines in COVID-19 vaccine sales, softer-than-expected sales of its RSV vaccine, setbacks in its pipeline, and heightened scrutiny against vaccines have also contributed to negative sentiment.

Demand for Moderna's vaccines for respiratory illnesses exhibits seasonality. The company is focusing on establishing a "seasonal respiratory vaccine franchise" to provide a stable revenue stream. The post-pandemic normalization of COVID-19 vaccine demand highlights the event-driven and seasonal nature of vaccine uptake for infectious diseases.

Moderna is a biotechnology company focused on mRNA therapeutics and vaccines. Its core business revolves around its mRNA platform, which develops human proteins, antibodies, and novel proteins to prevent, treat, and cure diseases. Major commercial products include the Moderna COVID-19 vaccine (Spikevax and mNEXSPIKE) and the RSV vaccine (Mresvia). Moderna has a robust pipeline with drug and vaccine candidates in development for infectious diseases, oncology therapeutics, and treatments for rare and autoimmune diseases.

Moderna's headquarters are in Cambridge, Massachusetts, and it has manufacturing units in the United States, Canada, the UK, and Australia. It has a commercial presence in 11 countries, including Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, the UK, and the U.S. The company plans to expand into ten additional markets across Asia-Pacific and Europe. Other office locations are in Melbourne, Paris, Munich, Tokyo, Warsaw, Seoul, Madrid, Basel, and Taipei.

Moderna has generally maintained a positive brand reputation, particularly due to its rapid development of a COVID-19 vaccine. The company has worked to demystify mRNA science through its "Welcome to the mRNAge" advertising campaign, aiming to raise brand awareness and highlight the broader potential of mRNA technology. Moderna's innovative approach, clinical efficacy, and adaptability in updating its vaccines have also contributed positively to its brand image.

Moderna's ownership includes institutional and individual investors. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Baillie Gifford & Co, State Street Corp, Fmr Llc, Morgan Stanley, and Geode Capital Management, Llc. Key individual and insider owners include Noubar Afeyan, Stéphane Bancel (CEO), and Robert Langer.